Search Results for "diagnosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Real-World Persistency on Tafamidis: An Analysis of US Insurance Claims Data

Unmet Need in a Contemporary Cohort of Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy Patients

Long-term Effects of Lumasiran on Kidney Stones and Nephrocalcinosis in Patients with Primary Hyperoxaluria Type 1

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN

This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in Patients With Cerebral Amyloid Angiopathy

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Musculoskeletal manifestations in patients with ATTR amyloidosis: Evidence from real-world analyses and clinical trials

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

Patient Demographics and clinical characteristics at enrolment in ELEVATE, an international registry of Acute Hepatic Porphyria

Enrollment Characteristics and Real-World Insights Into Disease Burden and Givosiran Treatment in Patients With Acute Hepatic Porphyria in the ELEVATE Registry

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: Post hoc analyses from the phase 3 ENVISION study through month 36

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6-months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: Post hoc Analyses from the Phase 3 ENVISION Study Through Month 36

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy

This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Dimension Analysis of EQ-5D in Patients with Acute Hepatic Porphyria Categorized by Annualized Attack Rate to Assess Any Relationship With Symptoms Occurring Between Attacks

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

Diagnosis of PH1 in CKD or Dialysis Patients

This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study

Long-Term Efficacy and Safety in the Phase 3 ILLUMINATE-B Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Impact of givosiran treatment on symptoms between acute attacks of acute hepatic porphyria as assessed by dimension-level analysis of EQ-5D data from the ENVISION study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "diagnosis"

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Diagnosis of PH1 in CKD or Dialysis Patients This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.

Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN

This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.

Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy

This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.

Diagnosis of PH1 in CKD or Dialysis Patients

This handout informs the consequences of PH1 systemic manifestations due to declining kidney function and how to diagnose PH1.